Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Bremelanotide
An FDA-approved melanocortin agonist for one specific sexual-health diagnosis — endlessly mis-sold as a general performance enhancer.
Melanotan II
A synthetic melanocortin peptide sold for tanning — unapproved everywhere, and routinely confused with genuinely approved melanocortin medicines.
How far human research has progressed
Bremelanotide
Approved (2019) with completed pivotal trialsMelanotan II
Limited early human study; no approved development programmeClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Bremelanotide
Not separately assessed; see the full profile.Melanotan II
Not separately assessed; see the full profile.Human research context
Bremelanotide
Approved (2019) with completed pivotal trialsMelanotan II
Limited early human study; no approved development programmeHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Bremelanotide
Melanotan II
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Bremelanotide
Melanotan II
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Bremelanotide
Melanotan II
Regulatory status (legal position, not proof it works)
Bremelanotide
Named regulators: FDA (US)
FDA-approved in 2019 (Vyleesi) for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women. That is the entire approval: it is not indicated for men, for postmenopausal women, or for general sexual performance enhancement.
Melanotan II
Check jurisdiction-specific details in the profile.
Not an approved medicine in any major region and identified by FDA as a bulk substance presenting significant safety risks for compounding. It must not be confused with the approved melanocortin medicines bremelanotide, afamelanotide and setmelanotide, each of which has its own narrow, specific indication.
Common claims
Bremelanotide
- · Improves sexual desire in premenopausal women with HSDD
- · Marketed online as a libido enhancer for everyone
Melanotan II
- · Tans the skin without sun exposure
- · Suppresses appetite
- · Increases libido
How settled our evidence rating is
Bremelanotide
Melanotan II
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Bremelanotide
No established human cancer signal within its approved use.Melanotan II
A recurring concern is that stimulating melanocytes could interact with melanoma risk. No human data demonstrate that Melanotan II causes cancer — and none establish it is safe in that respect. Unstudied is not reassuring.What this adds up to, in plain English
Bremelanotide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Melanotan II
The interesting work is in animals and lab studies. Treating it as an established human treatment is not supported by evidence.A comparison is not a recommendation